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1. Introduction 
The overwhelming impact the Human Immunodeficiency Virus (HIV) has on the world is 
undeniable – by the end of 2009 there were 33.3 million people living with HIV in the world, 
with 1.8 million deaths in that year alone (WHO 2010). In addition, the high rate of deaths 
can be directly attributed to the lack of available medications – only 36% of the infected 
population received adequate antiretroviral therapy (WHO 2009). Besides the known 
political and monetary issues at hand, the multiple number of HIV virus subtypes and sub-
subtypes that have been described are overwhelming pharmaceutical availability. In fact, 
most research completed on HIV therapies has occurred, and continues to occur, in Europe 
and America, targeting the HIV-1 strain, although much of the world population is also 
afflicted by HIV-2.  
To combat viral strain mutations, Highly Active Antiretroviral Therapy (HAART) has 
increased in complexity and effectively decreased deaths from opportunistic infections in 
those that are candidates for this treatment. However, these advances are tainted with 
metabolic long-term side effects, some of which are directly attributed to HIV Protease 
Inhibitors (PIs).  
HAART has been linked to cardiovascular complications in HIV-1 patients, and recent 
studies have shown that HIV PIs play critical roles in insulin resistance, dysregulation of 
lipid metabolism, and inflammation, which are all cornerstones of cardiovascular 
complications. In addition, HIV PI-induced atherosclerotic cardiovascular disease is 
becoming the leading cause of mortality in HIV-1 infected persons in developed countries. 
During the last decade, an extensive effort has been put forth to study HAART-induced side 
effects. Both in vitro and in vivo animal studies from our laboratory and others’ have linked 
HIV PIs with the activation of endoplasmic reticulum (ER) stress and oxidative stress as well 
as an increase in inflammatory cytokine production from several cell types including 
macrophages, hepatocytes, intestinal epithelial cells and adipocytes. However, the 
underlying cellular and molecular mechanisms remain to be fully identified and therapeutic 
strategies are currently unavailable. Understanding the root causes of HAART-associated 
metabolic syndrome and its potential implications for HIV-infected patients will be critical 
to the design of effective interventions to combat the metabolic and cardiovascular diseases 
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in a population chronically exposed to HAART. This chapter will discuss the current 
findings of HAART-associated metabolic complications and therapeutic challenges in the 
clinic.  
2. FDA approved antiretrovirals in sequence of viral cycle  
The first essential step in HIV infection of immune cells is fusion of the viral and cellular 
membranes. After an initial interaction, viral proteins utilize secondary receptors, especially 
CXCR4 (T cells) or CCR5 (macrophages), to gain entrance into the host cell. Maraviroc is a 
recently approved antiretroviral agent that inhibits fusion via binding and therefore 
prevents interactions with CCR5. Another, less commonly prescribed agent is Fuzeon 
(enfuvirtide), which binds to viral gp41. Due to the recent FDA approval of these two 
therapies, they will not be discussed in this chapter as there is little information on the long 
term clinical side effects of their usage. However, there is some positive evidence that there 
are minimal adverse metabolic effects.  
After entry into the cellular cytoplasm, the viral genome (two copies of a single-stranded 
RNA) is reverse-transcribed into DNA by the viral enzyme, reverse transcriptase (RT). The 
first anti-HIV drugs to come on the market inhibited this enzyme. There are currently three 
classes of RT inhibitors (RTI), nucleotide and nucleoside analogues (NRTI), as well as non-
analogues (NNRTI). NRTIs are analogues to deoxynucleotides which are incorporated into 
the growing DNA chain, but lack one significant motif, a 3’-hydroxyl group, which is 
essential in linking each deoxyribose in the chain. Without this hydroxyl group, NRTIs 
cause a halt in synthesis, terminating chain growth. NNRTIs, on the other hand, bind 
directly to the RT itself, inhibiting the function of this essential enzyme. 
The next step is integration of the newly synthesized DNA strand into the host genome by 
viral integrase. In 2007, the FDA approved Raltegravir, which directly inhibits this enzyme, 
and therefore does not allow latency of the virus in host cells. There has been some exciting 
evidence that Raltegravir has minimal side effects and may even reduce the side effects of 
some HIV PIs, as discussed later. 
Upon host cell activation, often in times of stress such as infection and inflammation, the 
integrated virus cuts itself from the host genome and begins the viral replication cycle. Here, 
the virus utilizes the host RNA polymerase to produce multiple copies of package-able RNA 
strands from the DNA sequence. At the same time, the host cell machinery is recruited to 
translate RNA into viral proteins that are necessary for virion production and release. After 
protein production, the viral protease cleaves long HIV proteins into functional segments. 
Viral protease is unique in that it recognizes substrates with multi-folded domains and 
cleaves between a tyrosine/proline or phenylalanine/proline, something which human host 
cell enzymes cannot accomplish. This allowed for the specific design of HIV protease 
inhibitors (PI). 
2.1 Trails to current recommendations 
Zidovudine, an NRTI, was the first drug approved in 1987, followed by approvals of 
zalcitabine, stavudine, and didanosine. The NRTIs seemed effective, yet the development of 
resistant strains caused a rebound of opportunistic infections in patients. In 1995, a major 
turning point occurred with the approval of HIV PIs ritonavir, saquinavir, and indinavir. 
Not only did these drugs work independently to help reduce viral load, but combination 
therapy with NRTIs drastically decreased opportunistic infections. This regimen is now 
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known as Highly Active Antiretroviral Therapy (HAART), although the combinations have 
increased in variety. The classic HAART regimen includes two NRTIs with one PI, though 2 
NRTIs with 1 NNRTI, or 3 NRTIs are also used. With the constant battle against resistant 
strains in the current HIV-infected population, addition of integrase or fusion inhibitors 
increases efficacy of these regimens, thus widening the arsenal of HIV drugs available to 
physicians. 
In addition to different classes of drugs, each class has also increased in variety. For instance, 
within HIV PIs, there are now two generations of drugs, peptidic and non-peptidic, all of 
which have a hydroxyl group that mimics the transition state structure of hydrolysis 
(Mastrolorenzo et al. 2007). The peptidomimetic class is large in itself, and inherently diverse 
in structure. For example, some (i.e. ritonavir) are less peptidic in nature, but enhance stability 
of PI binding to the enzyme. In contrast, others are more effective but the viral protease may 
easily mutate with their use. As PIs are discussed extensively in this chapter due to their 
correlation with metabolic side effects, we will quickly mention them here.  
Saquinavir (SQV) was the first PI approved by the FDA in 1995. Indinavir (IDV) reached the 
market in 1996 and, due to its efficacy with NRTIs, set the bar for HAART. Ritonavir (RITV) 
was marketed that same year, but currently is only given as a booster with other PIs as it 
inhibits cytochrome P450 (enzymes that metabolize most PIs and subsequently decrease 
their bioavailability). Nelfinavir (NFV) was marketed in 1997, and subsequently became the 
first PI to be recommended for pediatric patients. In 1999, Amprenavir (AMPV – now 
prescribed as prodrug fosamprenavir) was introduced. Atazanavir (ATZV) was approved in 
2003, and was the first PI approved for once-daily dosing, raising the bar for development of 
more convenient PIs. 
Lopinavir (LOPV) entered the prescription option in 2000. It was structurally designed for 
viral protease variants, but is similar to RITV. Due to low bioavailability, LOPV is 
prescribed only with a RITV combination. Now, the only form of LOPV available on the 
market is as a co-formulation pill, Kaletra (the first drug not available in single formulation). 
Kaletra was so successful in both drug-naïve and drug-experienced patients that it became 
first-line therapy in 2006, and now has only been surpassed by the newer non-peptidic PI, 
darunavir (DRV). Tipranavir (TRV) is the most recent PI, coming onto the market in 2006, 
but is only used in patients with resistant strains due to a high side effect profile.  
2.2 Side effects of antiretrovirals 
As the list of FDA approved antiretrovirals is long, so is the inventory of side effects. Even 
though the life expectancy of HIV-infected patients under HAART has been extended, the 
various HAART-induced side effects significantly affect quality of life. Therefore, treatment 
of HIV infection requires the balance between the beneficial effects of viral suppression and 
the drug-induced toxic effects.  
The most common side effects of HAART are attributable to the NRTI/NNRTIs. These 
include general side effects such as rash, anemia, nausea, vomiting, diarrhea, and sleep 
disturbances. More severely, it is not uncommon to observe liver toxicities, pancreatitis and 
neuropathy in certain patients, often with underlying risk factors. Furthermore, in the past 
decade there has been increasing concern over long-term HAART patients experiencing 
early-onset cardiovascular risk factors such as hypertension and insulin resistance. With 
parallel observations in the American population, some attributed these to environmental 
factors not due to the drugs. However, numerous large clinical trials have determined that 
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HAART can induce such drastic metabolic changes, the most common of which are 
components of the clinically defined Metabolic Syndrome. 
Metabolic Syndrome is a diagnosable syndrome that leaves patients at a high risk for heart 
attacks and strokes. To be diagnosed, according to the National Heart Lung and Blood 
Institute  criteria (Grundy et al. 2006), a patient must have 3 out of the 5 diagnoses: 
1. 35” central circumference in women, or 40” in men. 
2. A triglyceride level >150mg/dL. 
3. An HDL <50mg/dL in women or <40 in men. 
4. A blood pressure >130/85. 
5. High fasting blood glucose level or insulin resistance. 
Importantly, each component is an individual risk factor for atherosclerosis. 
In addition, some long term side effects have been given discrete labels, such as HIV-
associated lipodystrophy (Caron-Debarle et al. 2010). This has pathophysiologically been 
defined as selective damage of adipose tissue with subcutaneous fat loss and/or central fat 
accumulation. A large clinical trial, the Data Collection on Adverse Events of Anti-HIV 
Drugs (DAD), has provided more insight on this and other phenomena, giving the base for 
other investigators to continue examining the details. Specifically, lipodystrophy and 
dyslipidemia are now better explained. Contrary to the belief at the start of HAART, 
peripheral wasting is no longer attributed to viral wasting, but to NRTIs (stavudine and 
zidovudine) (Barbaro 2007; Carr et al. 2000; Martinez et al. 2001; Lee, Hanes, and Johnson 
2003); and fat accumulation is not a physiological phenomenon, but due to PI treatment 
(Mallon 2007; Mallon et al. 2003). Additional specific PI-induced side effects include glucose 
alterations and insulin resistance, which can lead to diabetes (DMII), hypertension, and 
cardiovascular (CV) dysfunctions (Calza, Manfredi, and Chiodo 2004; Friis-Moller et al. 
2003; Group et al. 2007). The bottom line from these investigations is that myocardial 
infarction is directly correlated with PIs, and not other components of HAART (Friis-Moller 
et al. 2003; Kaplan et al. 2007).  
3. HAART-induced dyslipidemia 
Alterations in serum lipids of the HIV infected population have been noted since the 
beginning of the ‘90s. Before treatments began, patients often had a decrease in LDL and 
HDL plasma concentrations. NRTI treatment alone seemed to increase LDL to presumable 
baseline levels, without any effect on HDL, yet multi-drug treatments tended to increase 
serum triglycerides. In the late ‘90s, effort was carried out to tease apart the effect of 
infection versus particular therapies. 
In the past decade, there has been an increase in average serum lipid levels in the general 
population due to poor diet and increasing age, and the HIV-HAART cohort is no different. 
In addition, the initial rise in serum lipid levels of HIV patients observed by clinicians was 
hypothesized to be immune reconstitution phenomena (Floris-Moore et al. 2006), which is a 
robust inflammatory response when HIV viral load decreases a few months to a year after 
treatment initiation. However, it has been found in numerous long-term and short-term 
studies, as well as in healthy versus HIV-infected persons, that HAART regimen, 
specifically PIs, induces dyslipidemia (Pere et al. 2008; Periard et al. 1999; Tsiodras et al. 
2000; Friis-Moller et al. 2003; Calza et al. 2003; Carr et al. 1999; Purnell et al. 2000; Group et 
al. 2007). Often, clinicians combat this phenomenon with lipid-lowering drugs. At the same 
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time, research has been attempting to determine which anti-HIV drugs induce the most 
change in lipid composition, and the mechanism underlying these changes.  
Lipid homeostasis is centrally controlled by the liver. When fats are consumed in the diet, 
lipids are packaged into chylomicrons in the intestines whose final fate is the liver through 
an apoE endocytosis pathway. In order to effectively transport these to peripheral tissues, 
the liver packages triglycerides (TGs) and cholesterol into very low density lipoproteins 
(VLDL). VLDLs circulate and the TGs inside are taken up by muscle and adipose tissue after 
hydrolysis by lipase. The remnants are called intermediate density lipoproteins (IDL) which 
can be endocytosed by cells or further converted to low density lipoproteins (LDL) by 
lipases on the surface of cells. LDLs are cholesterol rich particles endocytosed through apoB-
100, mostly in the liver or adipose tissue, and pathologically by macrophages. Another type 
of lipoprotein is high density (HDL), which is a way peripheral tissues ‘send back’ lipids, 
cholesterols, and proteins to the liver in an attempt not to be overloaded with these 
potentially toxic substances, as well as signal to the liver to stop synthesizing VLDLs. 
HAART-induced dyslipidemia appears to affect many aspects of this pathway. Some studies 
have found that NNRTIs may even be able to increase HDL (Garcia-Benayas et al. 2001), a 
clinical advantage for dyslipidemic patients leading some to want to alter regimens to 
decrease PIs and increase NNRTIs (Barragan, Fisac, and Podzamczer 2006; Walli et al. 2001). 
In fact, there were successful studies in switching from PI-based treatments to NNRTI or 
NRTI-only regimes with success in attenuating dyslipidemia (Walli et al. 2001; Ruiz et al. 
2001; Martinez et al. 2003). However, the effectiveness of PIs against HIV cannot be 
disputed. When PIs were added to the regimen in the mid-90s, there was a drastic decrease 
in patients who succumbed to opportunistic infections. The benefits of PIs far outweigh the 
side effects, but determining the mechanism behind these side effects may lead to 
alternative therapies in conjunction with PI use, or better-designed PIs.  
4. HAART impact on liver lipid metabolism 
The liver is a key organ in multiple processes, as well as the first organ to come into contact 
with ingested HAART medications. Hepatocytes are critical cells involved in lipid 
homeostasis, bile acid synthesis, gluconeogenesis, and metabolism of drugs. Therefore, 
alterations of normal cellular function can lead to global physiological consequences.  
In regard to hepatic lipid metabolism, the endoplasmic reticulum (ER) is a central player. 
The ER is a critical organelle in cellular function as it is responsible for proper protein 
folding, cellular calcium level, lipid synthesis, and the secretory pathway. Inducing ER 
stress is thus relatively simple via depletion of ER calcium stores, changes in ER lipid 
membrane composition, reactive oxygen species (ROS), or accumulation of misfolded 
proteins. When triggered, the ER signals to the cell through the unfolded protein response 
(UPR) to cope with the increased accumulation of unfolded or misfolded proteins by 
downregulating protein synthesis and upregulating the degradation pathway. However, the 
extended activation of UPR will result in apoptosis. 
UPR components identified in mammalian cells include three transducers [ER 
transmembrane kinase/endoribonuclease (IRE1), doubled-stranded RNA-activated protein 
kinase-like ER kinase (PERK), and activating transcription factor 6 (ATF-6)], as well as one 
master regulator [an ER chaperone protein (BiP/GRP78)]. In response to increased proteins 
in the ER lumen or calcium depletion, BiP/GRP78 releases the transducers, which induce 
differential control of gene transcription through transcription factors ATF-4 and spliced 
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XBP-1. Further activation of the downstream transcription factor GADD 153/CHOP will 
trigger apoptosis. 
In addition, sterol regulatory element-binding proteins (SREBPs) are transcription factors 
that also reside in the ER membrane. There are three isoforms derived from two genes: 
SREBP-1a, SREBP-1c, and SREBP-2. SREBP-1c and SREBP2 are the predominant isoforms in 
the liver and play a major role in regulating the expression of key genes involved in lipid 
and lipoprotein metabolism such as 3-hydroxy-3-methylgutaryl-CoA (HMG-CoA) synthase, 
HMG-CoA reductase, squalene synthase, acetyl-CoA carboxylase (ACC), fatty acid synthase 
(FAS), and nuclear receptors. Therefore, ER stress induction not only alters protein 
production, but also lipid metabolism. 
4.1 HIV PIs activate ER stress in hepatocytes 
In HAART-induced metabolic dysfunctions, many features are similar to those observed in 
nonalcoholic fatty liver disease (NAFLD). NAFLD is a clinical term to describe a 
phenomenon in which patients have a fatty liver similar in all aspects to an equivalent 
alcoholic subject. Induction of NAFLD has been described in a range of conditions, such as 
obesity and diabetes, as well as by a variety of drugs. In addition, NAFLD is strongly 
associated with hepatic insulin resistance, yet it is hard to distinguish which comes first – 
fatty liver or the insulin resistance. To complicate the issue further, the exact cause of lipid 
accumulation in the liver can range from increased non-esterified fatty acids (NEFA) coming 
mostly from adipose tissue, excess lipids from the diet in the form of chylomicrons, 
impaired lipid processing in hepatocytes (de novo lipogenesis or DNL), or decreased release 
of VLDLs. However, Donnelly and colleagues were able to demonstrate that the majority of 
hepatic lipids in patients with NAFLD came from peripheral NEFA and DNL, not the diet 
(Donnelly et al. 2005).  
This result is in agreement with HAART-induced NAFLD, as metabolic complications in 
these patients do not always seem to be correlated with diet. Importantly, although 
HAART-related NAFLD is not an entity of its own, many patients taking HIV PIs may have 
NAFLD with no symptoms, as does the majority of the overweight population. However, 
other patients progress to nonalcoholic steatohepatitis (NASH), which occurs with excess 
inflammation and scarring, potentially causing severe damage to the liver. Indeed, many 
studies have found NASH in greater than 50% of HAART-treated patients undergoing liver 
histopathological assessments (Ingiliz et al. 2009; Lemoine et al. 2006; Akhtar et al. 2008). 
HAART has been clearly shown to alter lipid and carbohydrate metabolism pathways, the 
underlying mechanism of NAFLD (Rector et al. 2008). Above all, NAFLD/NASH is most 
likely part of HAART-induced metabolic syndrome due to the strong correlations of 
hyperglycemia, insulin resistance, inflammation, and dyslipidemia. 
Not all HAART components are associated with inducing constituents of NAFLD. RTIs can 
induce liver enzyme dysfunctions, but most studies are inconclusive. The two drugs with 
the strongest correlation are two NNRTIs, nevirapine and EFV (Waters, John, and Nelson 
2007). Nevirapine-based HAART induces a faster liver fibrosis in those co-infected with 
hepatitis C (Macias et al. 2004), most likely due to a hypersensitivity reaction. In addition, 
some RTIs can have deleterious effects in the liver due to mitochondrial toxicities, which 
will not be discussed here due to a lack of correlation with metabolic side effects [reviewed 
in (Nunez 2010)]. However, HIV PIs are known to induce components of the metabolic 
syndrome, and hepatic alterations have been subsequently found to be at the core. Indeed, a 
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connection has been found between western diet-induced NAFLD and HIV PIs – the 
induction of ER stress (Erickson 2009). 
ER stress activation has been linked to various human diseases including NAFLD/NASH. 
Recent studies have shown that HIV PIs induce ER stress in many cell types including 
hepatocytes, macrophages and intestinal epithelial cells (Zhou et al. 2006; Zhou, Pandak, 
and Hylemon 2006; Zhou, Pandak et al. 2005; Zhou, Lhotak et al. 2005; Wu et al. 2010; 
Djedaini et al. 2009; Cho et al. 2009; Pyrko et al. 2007). We also have identified that HIV PI-
induced ER stress is partially due to depletion of ER calcium stores. In addition, activation 
of ER stress has been linked to the upregulation of SREBPs and dysregulation of lipid 
metabolism in hepatocytes.  
4.2 Autophagy in HIV PI-induced ER stress 
Autophagy is similar to the UPR as its main purpose is to protect the cell from deleterious 
stimuli, but has the ability to increase cellular damage or death when over-stimulated. It can 
be triggered in a number of ways, but the best described is that of perceived starvation. In a 
nutrient-rich environment, growth factors stimulate the eukaryotic cell and activate 
phosphoinositide 3-kinase (PI3K) Class I proteins. In turn, protein Akt-1 becomes activated 
through phosphorylation, leading to inhibition of autophagosome formation. Consequently, 
lack of nutrients leads to autophagy, resulting in engulfment of cellular particles or 
organelles for energy through lysosomal degradation.  
In addition to aiding cells during a starvation period, autophagy also helps regulate lipid 
stores. The exact mechanism behind autophagy-regulated lipid metabolism is not clearly 
defined, although it is known to be essential. When autophagy is inhibited in hepatocytes, 
lipids accumulate in droplets (Singh, Kaushik et al. 2009), and this is not due to increased 
triglyceride synthesis nor decreased VLDL secretions (Singh 2010). In addition, mice lacking 
autophagy in the liver have enlarged lipid-laden livers with increased triglyceride and 
cholesterol levels (Singh, Kaushik et al. 2009). Singh and colleagues have coined this process 
as lipophagy, in which lipid droplets are degraded through autophagy instead of lipolysis. 
Even further, components of the autophagosome may be necessary for lipid droplet 
formation, suggesting a flux of lipid metabolism in the cell dependent on this pathway 
(Shibata et al. 2009). 
In recent years, different laboratories focusing on dissimilar topics have independently come 
upon an autophagy and ER stress link. For one, autophagy offers another pathway other 
than proteasomes to degrade unfolded proteins (Kawakami et al. 2009; Yorimitsu and 
Klionsky 2007; Ding and Yin 2008). However, prolonged UPR activation has now been 
shown to lead to autophagy-induced cell death (Yorimitsu and Klionsky 2007) and 
inhibition of autophagy increases cell viability with prolonged ER stress (Price et al. 2010; 
Qin et al. 2010). The exact mechanism of how ER stress induces autophagy is still being 
investigated. Recently, it was found that ER stress activation can inhibit Akt 
phosphorylation, which is a dose-dependent response caused by some HIV PIs (Gupta et al. 
2007). However, the responsible protein(s) are still not known, and may be cell-type specific 
[reviewed in (Schleicher et al. 2010)].  
A recent study has found a strong link between activation of ER stress, increased autophagy 
induction, and increased SREBP activation leading to lipid overload in hepatocytes (Nishina 
et al. 2010), although the exact pathway linking these three was not experimentally 
addressed. Our laboratory has recently found that HIV PIs induce ER stress in hepatocytes, 
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leading to an increase in SREBP translocation to the nucleus, as well as induction of 
autophagy. However, the contribution of autophagy to HIV PI-induced metabolic syndrome 
remains to be determined and is the focus of our current studies [Figure 1].  
 
Fig. 1. Potential mechanisms of HIV PI-induced dysregulation of hepatic lipid metabolism.  
4.3 HIV PI-induced hepatic insulin resistance 
As discussed in the second section, HIV PIs have been directly linked to induction of 
HAART-metabolic syndromes, including lipodystrophy, glucose intolerance, and insulin 
resistance. These metabolic changes significantly increase the risk of DMII. There does not 
appear to be any one instigator in the spiral towards disease, but rather a mixture of 
increased lipolysis in the periphery, increased fat deposition in the liver and muscle, and 
peripheral and hepatic insulin resistance. In an attempt to tease these apart, a few clinical 
trials have found that HIV PIs first target a decrease in peripheral glucose uptake, although 
chronic treatment alters hepatic glucose production (Lee, Rao, and Grunfeld 2005; Woerle et 
al. 2003). Of specific note was an increase of fasting glucose – explained by endogenous liver 
production and decreased uptake in the periphery.  
DNL occurs in the absence of insulin, when the body is in a presumably fasting state. This 
pathway may be directly activated without absence of insulin as the instigator, such as 
through growth hormones activating Akt (potentially linking the findings of ER stress above) 
or simply through cellular insulin insensitivity. In particular, diabetic mice demonstrated an 
increase of Tribbles 3 (TRB3). Du and colleagues have found that TRB3 complexes with Akt, 
causing an inhibition of its activity (Du et al. 2003). As Akt mediates insulin signaling, the 
inhibition of its action results in inducing cellular insulin resistance. Importantly, ER stress can 
activate TRB3 directly through transcription factors ATF-4 and CHOP. Again, TRB3 activation 
would also lead to autophagy through inhibition of Akt activity. 
In addition to activating TRB3, ER stress also activates c-Jun N-terminal Kinase (JNK). JNK 
phosphorylates insulin receptor substrate (IRS-1), inhibiting its action of insulin-stimulated 
cell signaling (Ozcan et al. 2004). However, no current studies have been able to definitively 
show that HIV PI-induced ER stress leads to JNK activation, giving more support to the 
activation of TRB3 leading to both insulin insensitivity as well as autophagy. 
The link between insulin insensitivity in the hepatocyte and that of metabolic consequences 
seen in HAART patients is now coming together. It is understood that insulin suppresses 
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VLDL secretion, most likely through inhibition of ApoB100 from packaging TGs. Therefore, 
loss of insulin stimulation will invariably lead to increased VLDL secretions, contributing to 
dyslipidemia. In addition, insulin actively stimulates SREBP-1c, but it cannot be assumed 
that loss of the insulin activation will lead to a decrease in SREBP-1c and thus a decrease in 
lipogenesis. In contrast, HIV PIs may be continually stimulating the UPR, leading to a 
continuation of SREBP-1c activation and lipogenesis. Therefore, HIV PI effects in the liver 
may, in fact, contribute directly to dyslipidemia and insulin insensitivity.  
5. Impact of HAART on lipid metabolism in adipocytes 
Although the average individual despises adipose tissue due to the displeasing aesthetics, 
there is no denying its importance in overall health. Adipose tissue is a much more 
complex and important endocrine organ than originally thought, composed of adipocytes, 
macrophages, and endothelial cells communicating in a matrix of complex extracellular 
proteins and proteoglycans. To make issues more complex, there is a constant turnover of 
cells in tissue (10% of adipocytes renew each year (Spalding et al. 2008)) and an influx of 
macrophages from the periphery at times of adipocyte hypertrophy or stress (Sell and 
Eckel 2010).  
Different depots in the body have differing physiology (Hocking et al. 2010; Ray et al. 2009), 
most likely due to inconsistent derivations of tissue (Laharrague and Casteilla 2010; Billon et 
al. 2007). The differences between depots are seen both chemically and physiologically. It 
was found in the late ‘90s that preadipocytes isolated from different depots have different 
adipogenic induction responses (Adams et al. 1997) and gene expressions (Lefebvre et al. 
1998), but these differences are still not well understood. Physiologically, it has been long 
known that those with increased visceral adipose mass have a higher risk of cardiovascular 
disease, although those with the same BMI, but more subcutaneous mass do not have the 
same risk. In HIV treatment, different drugs have differential effects on fat tissue - the RTIs 
seem to decrease subcutaneous depots while the HIV PIs increase visceral adipose mass 
(Mallewa et al. 2008). The result is a substantial increased risk of CV disease in HAART-
treated patients, patients, which can be directly attributed to PIs can be attributed directly to 
PIs (Group et al. 2007). 
However, the differences that lead to detrimental risks are still not understood. Basic 
researchers have probed the physiology of visceral versus subcutaneous depots for a decade 
now with no concrete results. Nevertheless, these studies have provided more information 
on the metabolism of adipocytes and adipose tissue than ever before, allowing more 
understanding not only of HAART side effects, but also those of diabetes.  
5.1 Reverse transcriptase inhibitors 
Most persons that are not treated for HIV infection experience wasting syndrome, or the 
involuntary loss of a significant amount of weight with associated weakness. With the 
advent of RTIs, physicians were able to combat this uncomfortable aspect of the disease, but 
soon realized another phenomenon – that of a patient gaining weight only centrally or even 
directly loosing fat mass from the legs, arms, and face. In the mid ‘90s when clinicians first 
began observing this occurrence, they attributed it to the PI component of HAART. This 
explanation was in good logic as the observance came soon after PIs were added to the 
regimen. After further clinical studies, they were able to tease apart this phenomenon 
termed HAART-induced lipodystrophy, finding that RTIs induce peripheral fat loss while 
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PIs increased central obesity. The next phase of studies determined which drugs were most 
likely to induce these aesthetic mishaps. It is now known that thymidine analogue-NRTIs in 
particular are most strongly associated with lipo-atrophy of the extremities (Mallon 2007; 
Stankov and Behrens 2007; Mallal et al. 2000). Even more so, the mechanism behind this 
attribution seems to stem from mitochondrial toxicity leading to adipose cell death. 
Thymidine analogues are not initially active when they enter host cells as they must be 
phosphorylated before they can inhibit RT. This occurs in three steps, and generates two 
pharmacokinetic NRTIs in patients – active phosphate in cells and inactive drug in the 
plasma. Within the cells, intermediates occur that can have added effects, but the 
triphosphorylated NRTI is of most concern here, as it has been shown to directly inhibit 
mitochondrial DNA polymerase in many organs, including adipose (Kakuda 2000; Collins et 
al. 2004; Cote 2005). In fact, mitochondrial DNA was found to be depleted in HAART 
patient adipose biopsies (Nolan et al. 2003; Shikuma et al. 2001). However, this hypothesis 
seems insufficient to explain the total sum of physiological peripheral lipo-atrophy in 
patients. Therefore others have proposed supplementary mechanisms that may play a part 
in inhibition of the DNA polymerase for an additive effect on cells (Anderson, Kakuda, and 
Lichtenstein 2004; Lund and Wallace 2004). Most of these mechanisms are related to 
mitochondrial dysfunction, and may be partially due to the intermediate NRTIs. In addition, 
the balance of endogenous substrate with triphsophorylated NRTI may play a role, and help 
explain why only a certain proportion of patients experience lipo-atrophy (Anderson, 
Kakuda, and Lichtenstein 2004). 
Another component to this story includes inhibition of adipogenesis. Peroxisome 
proliferator-activated receptor-γ (PPARγ) is an essential transcription factor required for 
maturation from a pre-adipocyte to a mature adipocyte. It has been shown that thymidine 
analogues can downregulate this nuclear receptor, inhibiting adipogenesis. Later, it was 
found that mitochondrial toxicity is related to this inhibition, and may be directly linked. In 
other words, the thymidine analogues are perhaps not inhibiting PPARγ directly, but 
inducing mitochondrial toxicity that results in crosstalk to the nucleus to stop differentiation 
of cells (Viengchareun et al. 2007; Stankov et al. 2007).  
Importantly, the atrophy induced by RTIs may in fact contribute to HIV PI-induced NAFLD 
discussed previously. With the increase of cell death or inhibition of differentiation, there is 
a decrease in uptake of fats plus an increased release during cell death, increasing NEFA 
and contributing about 60% of the fats depositing in hepatocytes. Therefore, inhibition of 
RTI-induced cell death would not only aid a patient in an aesthetic discomfort, but also 
decrease the risk of NAFLD. 
5.2 HIV protease inhibitors 
As stated above, PIs appear to increase central adiposity, which is a major risk factor for CV 
disease. In addition, there are direct links of PIs and insulin resistance. The clinical 
significance of this has led to more research into PI-induced effects in adipose tissue than 
RTIs. Unfortunately, in the past decade we have only come a few steps closer to elucidating 
the exact mechanism of PI-induced adipose pathology. 
At the start of investigating these drugs, many researchers focused on the possibility that 
HIV PIs can inhibit adipogenesis and induce apoptosis, which may help explain lipo-
atrophy. However, depot-specific differences could not be explained and the conclusion that 
it was the NRTIs inducing the atrophy and not the PIs altered the focus of the field. In 
addition, the findings from these early investigations are still not conclusive. This is 
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explained by inherent difficulties in handling and processing adipose tissue, diversity in cell 
lines, and different subjective techniques used between laboratories. For example, some 
investigators found that RITV does not inhibit differentiation of adipocytes, while others 
stated that it significantly inhibits this pathway. Importantly, most laboratories focused on 
inhibition of differentiation, not the mechanism of this phenomenon nor how this effect in 
cell culture could be well correlated in the clinic. 
An important turning point in this field came through parallel research conducted in 
obesity, diabetes, and endocrinology. Major conclusions demonstrated that adipose tissue 
was a significant player in the inflammatory state and insulin resistance. HIV PI-
investigators began to turn from focusing on which drugs inhibited differentiation to the 
mechanism of HIV PI-induced lipid metabolism dysregulation, cytokine secretions, and 
connections to the metabolic syndromes seen in this patient population. Ensuing hypotheses 
included induction of ER stress, mitochondrial toxicity, inhibition of GLUT4, and autophagy 
induction. 
5.2.1 HIV PI-induced ER stress, inflammation, and insulin resistance in adipocytes 
As discussed in the previous section, ER stress activation is directly linked to dysregulation 
of hepatic lipid metabolism. In adipocytes, this is no different, and may be even more 
complex as cell maturation relies on lipids. In the preadipocyte state, the cell has more 
characteristics of a fibroblast than an adipocyte, in which it is elongated and located close to 
the blood vessel. At this stage, it releases minimal cytokines, and is relatively lipid droplet 
(LD) free. Upon induction of differentiation, the cell rearranges, begins to round when next 
to other adipocytes, and forms LDs. Although the complete understanding of LD formation 
is yet to be elucidated, it is known that they originate in some manner from the ER. It is also 
hypothesized that the two organelles stay connected in a manner that allows free exchange 
of lipids, but this hypothesis is not completely supported by evidence at this time. 
Either way, the close proximity of the ER to LDs, as well as the dependence of the ER on the 
production of neutral lipids, demonstrates how much the UPR can affect an adipocyte. In 
addition, adipocytes need constitutive activation of the UPR as the IRE1-XBP-1 pathway is 
essential in adipogenesis (Sha et al. 2009; Basseri et al. 2009), while overstimulation of the 
UPR can inhibit differentiation altogether (Shimada et al. 2007). This dependence on the 
UPR has not been demonstrated in hepatocytes and, in addition, another difference is 
observed with SREBP-1c. In adipocytes, SREBP-1c is actually downregulated in times of ER 
stress (Gregor and Hotamisligil 2007), as it is also a major player in adipogenesis.  
However, in addition to these differences, both cell types respond with some degree of 
insulin resistance upon UPR activation (Djedaini et al. 2009). In the fields of obesity and 
diabetes, we have come to realize that DMII is directly related to the inflammation and 
malfunction of overloaded adipose tissue. With increasing overload, adipocytes begin to 
hypertrophy, becoming stressed and signaling this with a release of proinflammatory 
cytokines. These cytokines cause an infiltration of circulating macrophages, which engulf 
over-stressed or dying cells, forming characteristic crown-like structures. Interestingly, HIV 
patients on HAART therapy appear to be in the same state as an obese individual in terms 
of inflammatory and dysfunctional adipose tissue. Patients often have a decrease in insulin 
sensitivity, as well as having dyslipidemia and liver disease as previously discussed. These 
factors can also be teased apart from over-nutrition, as shown in the D.A.D. studies, among 
other clinical investigations.  
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HIV PIs have been repeatedly shown to induce ER stress, and the results in our laboratory 
support others’ work. This activation has been shown to be directly linked to alterations in 
SREBP-1c processing in adipocytes, as well as suggested to be the cause of inhibition of 
differentiation observed with these drugs. In addition, the inflammatory cascade is induced 
in adipocytes treated with HIV PIs (Jones et al. 2005; Kim et al. 2006; Leroyer et al. 2011). The 
inflammatory state is highly predictive of onset of insulin resistance, and once again this 
induction is also directly linked to ER stress. In fact, activation of the UPR can induce 
inflammatory activation through the JNK pathway as stated previously. Additionally, 
cytokine release from neighboring cells can induce ER stress in the host cell, causing a 
vicious cycle. 
A key study in this field was done by Djedaini and colleagues, in which they treated human 
adipocyte cells with LOPV. They noted both increased activation of ER stress and decreased 
IRS1 phosphorylation, as well as reduced glucose uptake (Djedaini et al. 2009). What linked 
these phenomena was eIF2-α phosphorylation – a key protein activated during the UPR. 
When these investigators inhibited this phosphorylation with a specific molecule, salubrinal, 
they were able to decrease IRS1 phosphorylation slightly. However, when done in 
conjunction with minimal concentrations of LOPV, there was a significant decrease of IRS1 
phosphorylation, demonstrating a synergistic effect of the two drugs.  
Activation of the UPR leading to a decrease in insulin signaling may only be part of the 
story. Others have shown that PIs can actually inhibit the glucose transporter directly 
(Hertel et al. 2004). It has been proposed that this inhibition induces a starvation-like state in 
the cell with the decrease of intracellular glucose, causing activation of ER stress. This would 
lead to a decrease in insulin signaling, propagating insulin resistance further. At this point, 
adipocytes would rely heavily on lipids, hydrolyzing triglyceride stores and thus increasing 
NEFA release, causing lipotoxicity and insulin resistance at the physiological level. Despite 
these findings, more research is obviously needed to determine which pathway or proteins 
HIV PIs induce/inhibit when they first come into contact with an adipocyte. Only then can 
we be certain of the consequences of a given structure on the drugs currently on the market. 
5.2.2 Adiponectin and autophagy 
Adipocytes release not only pro-inflammatory cytokines, but also the anti-inflammatory 
cytokine adiponectin. Adiponectin is unique in a number of ways. It is exclusively secreted 
by adipose tissue and is negatively correlated with diseases such as atherosclerosis and 
insulin resistance. In overexpanded or stressed tissue, there is a decrease of adiponectin 
secretion (Kern et al. 2003), and an increase of macrophage-inducing TNF-┙, IL-6, and MCP-
1, implicating inflammatory diseases such as atherosclerosis and insulin resistance. 
HIV PIs have been repeatedly reported to decrease adiponectin, from the RNA level to 
secretion. Our laboratory has also noted this phenomenon, as well as found a substantial 
increase in IL-6 secretion in mouse adipocytes treated with HIV PIs for 48 hours, in a dose-
dependent manner. MCP-1 and TNF-┙ mRNA levels also increase. This is just one more 
piece of evidence that HIV PIs induce a pro-inflammatory state in adipose. 
Interestingly, adiponectin can alleviate ER stress (Zhou et al. 2010). Zhou and colleagues 
found in their cellular studies that ER stress initiation is sufficient to decrease adiponectin 
release. In animal models, they reported stabilization of adiponectin further decreased 
obesity-induced ER stress in adipose tissue. Moreover, induction of autophagy could 
alleviate ER stress responses in the cell, stabilizing adiponectin secretions. 
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As discussed previously, increasing evidence points to autophagic dysregulation as a 
component of altered lipid metabolism in cells. In adipocytes, there is a constitutive base of 
autophagy aiding in the recycling of lipid stores. Indeed, with a decrease in autophagy in pre-
adipocytes, there is a resulting inhibition of adipogenesis (Singh, Xiang et al. 2009). In vivo 
animal studies from the same group found a complete reduction of adipose mass when they 
induced a decrease in the autophagy pathway, resulting in smaller adipocytes and altered LD 
morphology. This is in seeming opposition to what occurs in the liver with a decrease in 
autophagy and may be best explained best by Singh and colleagues. They detail the need for 
autophagy to control adipose mass so lipids can be continually stored in adipose tissue, while 
in the liver, autophagy attempts to decrease TG accumulations (Singh 2010). 
5.3 Other HIV PI effects in adipocytes 
Although ER stress activation represents an important cellular mechanism underlying HIV 
PI-induced side effects in adiopocytes, HIV PIs may also influence cellular lipid metabolism 
through other mechanisms, such as mitochondrial toxicity. In this realm, most investigators 
who are proponents of this mechanism found concurrent inhibition of adipocyte 
differentiation with increased markers of mitochondrial dysfunction (Viengchareun et al. 
2007). When considering this hypothesis, however, the close tie of ER and mitochondrial 
homeostasis must be contemplated, especially in the case of the apoptosis cascade. Indeed, 
some have shown the same close connection when mitochondrial dysfunction leads to the 
UPR (Burkart et al. 2011), and likewise the UPR has been shown to induce mitochondrial 
dysfunction (Lee et al. 2010). This tight interplay often makes it difficult to discern where the 
initial damage occurs, but it is irrefutable that ER stress activation plays a major role. 
Another mechanism proposed is inhibition of PPAR┛ activity that leads to inhibition of 
differentiation. As stated before, many investigators discovered that RTIs and PIs were able 
to decrease the capability of adipogenesis. In these studies, it was found that PIs could 
inhibit PPAR┛ activity, and this was not through direct interaction[reviewed in (Caron et al. 
2009)]. Affecting PPAR┛ will alter the cell physiology, such as a decrease of adiponectin 
secretion and alteration of lipid metabolism. However, without demonstrating a direct 
pathway of HIV PI-induced PPAR┛ downregulation, it is difficult to pursue this mechanism 
when there are also other promising pathways in the works. 
6. HIV PIs increase inflammation at the vasculature and alter macrophage 
lipid metabolism 
Macrophages are key cells involved in atherosclerotic plaques. Initiation of a plaque can 
occur very early, when the endothelial lining becomes damaged or inflamed, inducing 
leukocyte infiltration. The damage is often attributed to oxidized lipoproteins in the 
bloodstream, occurring with high LDL levels and decreased anti-oxidants. After initial 
damage, macrophages localize to the area. In addition to their innate role to induce 
inflammation in the process of healing, macrophages will also take up circulating lipids that 
are not being properly processed by peripheral tissues. Macrophages will keep 
accumulating lipids, expanding and releasing pro-inflammatory cytokines that call in more 
macrophages, all the while not ‘fixing’ the initial problem of damaged endothelium. As the 
plaque builds, more lipids tend to accumulate in the given area and stability decreases, 
having the potential of completely restricting flow or dislodging. 
www.intechopen.com
 
Recent Translational Research in HIV/AIDS 
 
266 
Patients taking HIV PIs have been found to have accelerated atherosclerotic lesions. An 
important causative factor is most likely the dyslipidemia discussed previously, potentially 
inducing initial damage, although direct influence on the endothelial layer could also be at 
fault. In fact, numerous clinical studies have noted decreased endothelial function in 
HAART-treated patients. This decrease has been directly attributed to the PI component 
(Teixeira et al. 2009). In cell culture investigations, it has been found that PIs can directly 
induce apoptosis of vascular smooth muscle cells, which could contribute to both 
endothelium dysfunction as well as plaque instability, maybe through increased reactive 
oxygen species (Rudich et al. 2005). 
Once the initial damage ensues at the endothelium, macrophages can migrate through the 
endothelial layer into the intima and begin secreting inflammatory cytokines as well as 
developing scavenger receptors. These receptors are directly responsible for LDL uptake in 
macrophages, leading to foam cell formation. In regard to macrophages, HIV PIs actually 
have multiple affects. One of the more important of these was discovered by Dressman et al. 
who found that PIs actively induce CD36 (Dressman et al. 2003). CD36 is a fatty acid 
transporter in metabolically active tissues and, in macrophages, it binds and endocytoses 
oxidized LDLs. This directly leads to the formation of foam cells, which are at the core of 
plaques. 
In addition to inducing CD36, HIV PIs can increase foam cell formation via other pathways. 
HIV PIs have been shown by several investigators to increase active SREBPs in 
macrophages. Our laboratory has demonstrated that HIV PI-induced upregulation of 
SREBPs occurs through the activation of ER stress (Zhou, Pandak et al. 2005). In addition, 
PIs were found to decrease cholesterol efflux in foam cells by inhibiting scavenger receptor 
B1 and caveolins (Wang et al. 2007). Thus, PIs can both induce the intake and inhibit the 
export of the ingredients of a foam cell. 
Previous findings in our laboratory demonstrate that inner-membranes are overloaded with 
cholesterol in HIV PI-treated macrophages, and ER calcium stores depleted. Taking the 
above together, we hypothesize that HIV PIs induce cholesterol overload in macrophages, 
leading to an alteration in cholesterol composition of the ER membrane. As stated before, a 
slight alteration in membrane composition can induce the UPR, which would lead to an 
increase of SREBP-1 in macrophages, causing lipid overload and increasing foam cell 
formation of these cells. In addition, a proportion of these cells would die through the 
apoptotic pathway, inducing an unstable plaque, and a basis for the drastic side effects seen 
with these drugs. 
7. Metabolic disease, cardiovascular dysfunction, and concluding remarks 
As demonstrated throughout this chapter, PIs have drastic effects in multiple cell types and 
tissues. In addition to those listed above, PIs have also been shown to increase pro-insulin 
secretions from ┚-cells, demonstrating their altered functions (Behrens et al. 1999). It is 
postulated that PIs fist induce a transition from normal to impaired glucose tolerance due to 
insulin resistance induction in the liver and adipose tissues. With worsening glucose 
resistance, more insulin must be secreted, and over time this leads to ┚-cell dysfunction, 
which can be demonstrated by the release of inactive pro-insulin. However, as some 
investigators have shown direct effects of HIV PIs on the ┚-cell, it is possible these 
mechanisms are occurring simultaneously, accounting for the more rapid induction of 
insulin resistance seen in this patient population (Schutt et al. 2004).  
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In any case, there is no doubt that HAART has decreased total mortality in HIV-infected 
persons, but determining the mechanism behind life-altering side effects could help improve 
therapies. Also, not all HIV PIs have the same degree of metabolic disease-inductions; such 
as AMPV, which has the least effect on lipid metabolism and does not need a RITV booster. 
As mentioned previously, some have actually proposed to switch to NNRTIs and leave out 
the PIs for favorable lipid profiles in patients. Even more, we have recently shown that 
Raltegravir can actually mitigate HIV PI-induced ER stress, relieving lipid metabolism 
dysregulation in hepatocytes (Cao et al. 2010). 
This leaves the question of cost versus benefit. HIV-specialists are sure to argue that some of 
the PIs that are controversial are keeping their patients’ morbidity drastically down. 
Without these particular drugs, the chance of increased viremia and viral mutations is too 
large. Switching to AMPV, for instance, is not always feasible. In addition, although we 
have shown the potential of Raltegravir against the cellular side effects, this might not 
feasibly translate into the clinic due to pill-burden and expense. Therefore, physicians 
continue to push exercise and lipid-lowering drugs. Development of better therapeutic 
strategies for HIV infection and HAART-induced metabolic syndrome requires more 
extensive studies and efforts.  
 
 
Fig. 2. Summary of HIV PI-induced pathological effects. 
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